HMG-CoA reductase inhibitors in kidney transplant recipients receiving tacrolimus: statins not associated with improved patient or graft survival

  title={HMG-CoA reductase inhibitors in kidney transplant recipients receiving tacrolimus: statins not associated with improved patient or graft survival},
  author={Nizar Younas and Christine M. Wu and Ron Shapiro and Jerry Mccauley and James R. Johnston and Henkie P. Tan and Amit Basu and Heidi M. Schaefer and Cynthia Smetanka and Wolfgang C. Winkelmayer and Mark Unruh},
  journal={BMC Nephrology},
  pages={5 - 5}
BackgroundThe beneficial effects of early statin use in kidney transplant recipients, especially those on tacrolimus-based immunosuppression, are not well established. We evaluated the predictors of statin use following kidney transplantation and examined its association with patient and allograft survival.MethodsWe examined 615 consecutive patients who underwent kidney transplant at our institution between January 1998 and January 2002. Statin use was assessed at baseline and 3, 6, 9, and 12… 

A possible role for statin therapy in solitary pancreas transplantation?

Effect of Statins on Patients and Graft Survival in Kidney Transplant Recipients: a Survival Meta-analysis.

Meta-analysis showed that the use of statin correlated independently with improved patient and graft survival after kidney transplantation, and may provide valuable information on the potential beneficial effects of statins in kidney allograft recipients.

Dyslipidaemia among renal transplant recipients: cyclosporine versus tacrolimus.

The occurrence of new onset hyperlipidaemia is similar in renal transplant recipients receiving either cyclosporine or tacrolimus in first 3 months post-transplant, but there is room for more research in this field as dyslipidaemic following successful renal transplantation is a frequent and persistent complication.

HMG-CoA Reductase Inhibitors in Chronic Kidney Disease

The aim of this review is to assess current literature on the use of statins in CKD and end-stage renal disease and the potential association with decreased cardiovascular events.

Restoration of renal function does not correct impairment of uremic HDL properties.

This study demonstrates that HDL from kidney recipients is uniquely altered at the molecular and functional levels, indicating a direct pathologic role of HDL that could contribute to the substantial cardiovascular risk in the transplant population.

Short-Term Complications and Management Medical Complications

This chapter summarizes late post-KT medical complications, focusing on the importance of early diagnosis and efficient management of these complications in the outpatient setting in improving outcomes.

How to demonstrate the reversibility of end-organ function before implantation of left ventricular assist device in INTERMACS profile 2 patients?

Two patients whose end-organ dysfunction had been eventually demonstrated to be reversible by invasive procedures such as transluminal liver biopsy or transient insertion of intra-aortic balloon pumping are reported.



Patient survival after renal transplantation III: the effects of statins.

  • F. CosioT. Pesavento S. Lemeshow
  • Medicine, Biology
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2002
Renal transplant recipients treated with statins have a 24% better survival than patients who do not receive these drugs, and cholesterol significantly modified the relationship between statin use and patient survival.

Statin use is associated with improved function and survival of lung allografts.

The data suggest statin use may have substantial clinical benefits after pulmonary transplantation, and total cellularity, as well as proportions of inflammatory neutrophils and lymphocytes, were significantly lower in bronchoalveolar lavages of statin recipients.

Impact of Statin Treatment on 1-Year Functional and Histologic Renal Allograft Outcome

Early introduction of statins may be associated with improved 1-year graft outcome in the first year posttransplantation, as shown in patients with uniform immunosuppression who underwent transplantation at the authors’ unit from 1997 to 2002.

Statin use is associated with prolonged survival of renal transplant recipients.

Statin use was associated with prolonged patient survival, but no difference in graft survival was detected, and Multivariable Cox regression demonstrated that statin use was independently associated with lower mortality rates.

Statins in Solid Organ Transplantation: Is There an Immunosuppressive Effect?

  • J. Kobashigawa
  • Medicine, Biology
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2004
In conclusion, statins appear to have outcome benefits in heart and kidney transplant patients; however, firm evidence for a clinical immunosuppressive effect is lacking.

Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients.

  • L. RendersI. Mayer-Kadner I. Hauser
  • Medicine, Biology
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2001
In the study population both statins were very effective in lowering elevated LDL cholesterol levels, and Cerivastatin did not influence CsA blood trough levels, whereas atorvastatin increased C sA levels in four of 10 patients.

Acute renal allograft rejections, a role for statins?

  • H. HoldaasA. Jardine
  • Biology, Medicine
    Minerva urologica e nefrologica = The Italian journal of urology and nephrology
  • 2003
Recent clinical and experimental data will be provided for assessing statins as immunosuppressive agents, and more recent clinical placebo controlled studies have failed to confirm the initial optimism of this effect of statins.

The effect of pravastatin on acute rejection after kidney transplantation--a pilot study.

It is suggested that pravastatin exerts an additional immunosuppressive effect in kidney transplant recipients treated with cyclosporine-based Immunosuppression.

Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation.

  • H. HoldaasB. Fellström C. Gimpelewicz
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2005
The data support an early introduction of fluvastatin therapy in a population of transplant recipients at high risk of premature coronary heart disease and total time on renal replacement therapy.